Objective: To identify, review and critically appraise model-based economic evaluations of all types of interventions for people with dementia and their carers.
Introduction
Economic considerations play an important role in financing and service provision for the diagnosis of dementia, and the treatment and care available for people with dementia.
Economic evidence is presented in many formats, including cost of illness studies, within-trial cost effectiveness analyses, and model-based economic evaluations. We focus here on the latter and the use of decision-analytic models to assess the cost effectiveness of interventions for dementia. The use of model-based evaluations is attractive in a health policy context as it provides an explicit framework to systematically synthesise evidence available from multiple sources, and to estimate and compare longer term outcomes (e.g. life-expectancy, quality adjusted life years) and inputs (costs) for alternative interventions and/or treatment pathways.
Model-based economic evaluations are commonly used to support decision-makers in a health policy context, where assessment of effectiveness and cost effectiveness in a policyrelevant context is required.
The usefulness and validity of the evidence available from model-based evaluations is dependent on the methods and data used to estimate and report the expected costs, outcomes and cost effectiveness of interventions. Decision-makers must assess the quality of the model-based evaluations and be familiar with the pros and cons of the evaluations when interpreting findings and using them to inform health policy. There is a growing literature on the use of decision-analytic models in the dementia context, including a number of high-quality systematic reviews. While each of the available reviews has focused on a distinctive segment of the care continuum, i.e. diagnosis (Handels et (Sopina and Sørensen, 2018) , they shared similar objectives and a number of common themes. A majority of reviews aimed to understand the analytical approaches used to evaluate cost effectiveness through providing a detailed description of study characteristics, methodologies, model elements and main findings. Common findings across reviews have been that (i) many studies failed to present sufficient information to fully assess methodologies used, thus increasing the uncertainty surrounding the interpretation and generalisation of the results, (ii) considerable variation exists in methodological assumptions applied and target populations among studies, preventing a meaningful comparison of cost effectiveness results, and (iii) evaluations should use better quality and up-to-date data, particularly outcome data that better reflect the breadth of dementia symptoms. Prior reviews have taken a varied approach to the critical appraisal and assessment of methods, with few providing a comprehensive quality assessment of modelling methods and reporting practices against published decision-analytic models in dementia.
None of the prior reviews have reported across the full continuum of dementia care, from prevention, screening, early detection and diagnosis, to treatment and care programs for people with dementia and their carers.
In the current review we present a comprehensive overview of contemporary model-based economic evaluations of dementia interventions. We systematically review the literature reporting decision-analytic models used in economic evaluation of interventions for people with dementia and their carers (informal and family carers) across prevention, early detection, diagnosis and treatment and care strategies, including all types of dementia. Additionally, we critically assess the modelling methods used and reporting quality against good practice guidance on methods for decision-analytic modelling in health technology assessment, across key domains of model structure, data, and model consistency.
Methods

The systematic search and review of the literature
We have undertaken the systematic review in line with the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009 ). The systematic review was registered in PROSPERO international prospective register of systematic reviews (ID: 42017059154) in April 2017. The search strategy and keywords are presented in Table A1 .1 (Appendix 1, published as supplementary material online attached to the electronic version of this paper at https://www.cambridge.org/core/journals/internationalpsychogeriatrics). The search was applied to literature available up to February 2018, in the electronic databases of MEDLINE, CINAHL, Cochrane Library, Embase, PsycINFO, Econlit, HTA database, CEA registry and PubMed. Reference lists of identified publications were checked for additional articles meeting the inclusion criteria.
Inclusion criteria (Table A1 .2, Appendix 1) were (i) evaluations of interventions for people with dementia and/or their carers, covering surveillance, screening, early diagnosis, treatment, management and care, where (ii) economic evaluation used a decision-analytic model-based framework. The identification of studies was undertaken by two independent reviewers, who initially screened the titles and abstracts for eligibility. A study was included if both reviewers agreed that it met all the inclusion criteria. Dissimilarities in reviewers' conclusion were resolved by discussion and/or examining the full article. Full texts of all included studies were reviewed independently by both reviewers. Resulting citations and reference lists in these reviewed studies, studies that published systematic reviews and meta-analyses were examined to ensure that no eligible studies were missed. Both reviewers systematically and independently documented the properties of the included studies.
Quality assessment of decision-analytic models
For quality assessment of included studies, we used the framework for assessment of good practice in decision-analytic models in a health technology assessment context, presented by Philips et al., (2006) , (hereafter, referred to as the Philips checklist). The checklist is a broad framework which assesses three key dimensions of modelling: structure, data (including uncertainty) and consistency. It includes 58 items; with 9 distinct areas for model structure (23 items), 11 areas for data (30 items), and 2 areas for model consistency (5 items). See Table   A1 .3 (Appendix 1) for detail on the Philips checklist. This checklist was used because of its relevance to the HTA context (Philips et al., 2004) , and as it is considered to be consistent with the ISPOR principles of good practice for decision-analytic modelling for health care evaluation (Caro et al., 2012; Weinstein et al., 2003 ).
The quality assessment using the Philips checklist was conducted by two independent reviewers. Differences between the two reviewers' responses for each item were resolved by discussion and/or consultation with a third reviewer. We followed the questions and examples presented in Philips et al., (2004, 2006) to score a response for each item (Y=Yes, N=No, U=Unsure, NA=Not Applicable). The scoring decisions for a study were also influenced by the available literature up to that point in time, particularly with respect to other published models, data sources, and best practice guidelines. The standards for assessment of uncertainty increased over time as the number of published studies using competing models increased. 
Results
Basic properties of studies included in the systematic review
We identified 67 studies that met the inclusion criteria (evaluating a dementia intervention We identified 19 studies evaluating strategies for prevention (Zhang et al., 2011) to biomarker (Aβ41, cerebrospinal fluid) detection. In these studies, the main target populations were elderly people or those with mild cognitive impairment.
Almost all studies used a cost utility framework (48/67), in which the primary outcome was quality adjusted life years, or a cost effectiveness analysis (15/67). Four studies used either cost benefit analysis or evaluated either outcomes or cost only. In cost effectiveness studies, the final outcomes were measured by clinical endpoints such as life years, the number of accurate diagnoses, and the number of years before full-time care or before institutionalisation.
The most commonly used modelling framework was a Markov state transition model (52/67), followed by a decision tree approach (12/67). Four studies combined a decision-tree (for diagnosis) with either a Markov or a discrete event simulation model (for dementia progression). Six studies used a discrete event simulation (DES) framework, four of which were based on the model structure developed in ( Neuropsychiatric Inventory) were used in five Markov transition models to define health states (nine to 12 health states), and in six DES models to initiate events and assign attributes to patients (see Table A2 .1, Appendix 2 for more details).
Similar to other areas of disease modelling literature, models in this dementia literature relied upon disease progression data estimated from observational studies, many of which date from 
Quality assessment of decision analytic models using the Philips checklist
We conducted quality assessment using the methodological; structural; heterogeneity; and parameter), validation of internal consistency and calibration against independent data. Only two studies scored "Yes" in more than 85% of all items; both of them were comprehensive (long) health technology assessment (HTA) reports submitted to NICE (Bond et al., 2012; Loveman et al., 2006 ). They both explicitly described a systematic approach to the literature search and thorough consideration and selection of models, parameters, assumptions, and pre-modelling methods, which were commonly omitted in other publications. We present the full quality assessment findings in Table A2 .2 (Appendix 2), and a summary of key observations on the changes of modelling and reporting quality over time in Table 1 .
INSERT FIGURE 3
INSERT Data: Modelling quality has improved over time. Strong improvements were observed in the reporting of baseline data, quality of life weights and analysis of parameter uncertainty. While the adoption of good modelling and reporting practices is also reflected in critical areas such as selecting data sources and using appropriate techniques for pre-modelling analyses, a majority of studies simply reported the modelling decision/approach without providing a rationale. For instance, while more than 80% of all studies discussed, reported and referenced the model data properly (items D11, D2c1, D31, D33, and D35), fewer than 20% provided sufficient justification for its use (items D12, D2a4, D2b2, D2b3, D2c3, D32, and D42). 
Discussion
Decision-analytic models have been used widely in the economic evaluation of dementia interventions in the past three decades. While this approach has been attractive in a health policy context, the validity of (cost-effectiveness) findings depends entirely on the modelling quality. That is, how well the model addresses the decision problem through modelling of disease progression and treatment pathways, and capturing the relevant costs and outcomes, and whether or not the model can be validated against external data.
As expected, recent studies (e.g., those published after 2010) showed significant improvement in terms of modelling quality and reporting standard, which may be a result of the introduction of guidelines on decision-analytic modelling and good practice checklists (e.g. CHEERs, 
Conclusion
We identify an expanding literature on model-based evaluations of interventions for dementia.
The literature is predominantly reporting on pharmaceutical interventions for Alzheimer's disease, but there is a growing literature for dementia prevention and non-pharmacological interventions. We provide a comprehensive summary and a critical review of the literature, finding that reporting of decision-analytic models has improved with the recent introduction of checklists and guidelines. However, we find some important aspects of model reporting still require substantial improvement, including justification of key model components and data selection. Findings here clearly demonstrate that decision-makers using model-based evaluations of dementia care need to critically appraise and understand the methods and data applied, and the limitations of any evaluation to ensure they are used, interpreted and applied appropriately. 
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